REVEAL Lite 2

1. Dapagliflozin decreases REVEAL Lite 2 in humans (-0.66, 95% CI [-1.25, -0.06]).

   Human trialPAH or CTEPH on background vasodilator therapy10 mg daily12 weeksn = 52

   Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 31 Aug 2026

Dapagliflozin →